## Amendments to the Claims:

- 1. (Currently amended) An unlipidated cytomegalovirus vaccine which comprises a fusion peptide composed of a T helper epitope fused to a CMV CTL.
- 2. (Previously presented) A cytomegalovirus vaccine of claim 1 wherein said T helper epitope is PADRE (SEQ ID NO:2).
- 3. (Withdrawn) A cytomegalovirus vaccine of claim 1 wherein said T helper epitope is a tetanus epitope.
- 4. (Withdrawn) A cytomegalovirus vaccine of claim 3 wherein said tetanus epitope is selected from the group consisting of tetanus heavy chain (590-603), tetanus heavy chain (615-629), tetanus heavy chain (639-652) (SEQ ID NO:4), tetanus heavy chain (830-843) (SEQ ID NO:3), and tetanus heavy chain (947-967).
- 5. (Previously presented) A cytomegalovirus vaccine of claim 1 wherein said CMV CTL epitope peptide is selected from the group consisting of pp65 $_{13-24}$  (SEQ ID NO:15), pp65 $_{186-196}$  (SEQ ID NO:16), pp65 $_{188-195}$  (SEQ ID NO:17), pp65 $_{265-275}$  (SEQ ID NO:18), pp65 $_{363-373}$  (SEQ ID NO:19), pp65 $_{369-379}$  (SEQ ID NO:20), pp65 $_{367-379}$  (SEQ ID NO:21), pp65 $_{495-503}$  (SEQ ID NO:1) and pp65 $_{417-426}$  SEQ ID NO:22).
- 6. (Previously presented) A cytomegalovirus vaccine of claim 5 wherein said CMV pp65 CTL epitope is pp65<sub>495-503</sub> (SEQ ID NO:1).
- 7. (Original) A cytomegalovirus vaccine of claim 1 which further comprises a DNA adjuvant.

- 8. (Previously presented) A cytomegalovirus vaccine of claim 7 wherein said DNA adjuvant is selected from the group consisting of SEQ ID NO:8, SEQ ID NO:9 and SEQ ID NO:10.
- 9. (Original) A cytomegalovirus vaccine of claim 1 which further comprises a pharmaceutically acceptable carrier.
- 10. (Currently amended) An unlipidated fusion peptide comprising a T helper epitope fused to a CMV CTL epitope peptide.
- 11. (Previously presented) A fusion peptide of claim 10 wherein said T helper epitope is PADRE (SEQ ID NO:2).
- 12. (Withdrawn) A fusion peptide of claim 10 wherein said T helper epitope is a tetanus epitope.
- 13. (Withdrawn) A fusion peptide of claim 10 wherein said tetanus epitope is selected from the group consisting of tetanus heavy chain (590-603), tetanus heavy chain (615-629), tetanus heavy chain (639-652) (SEQ ID NO:4), tetanus heavy chain (830-843) (SEQ ID NO:3), and tetanus heavy chain (947-967).
- 14. (Withdrawn) A method of modifying the immune response of a mammal to CMV comprising administering an effective amount of a vaccine of claim 1.